Shown are the differences in total-body 18F-FDG uptake via PET in all twelve subjects when they were given placebo (left), 200 mg of the β3-adrenergic receptor agonist mirabegron (center), or mild cold (right). Of note, subject #6 withdrew from the study several weeks after the efficacy of mild cold exposure and mirabegron were evaluated and did not receive placebo. comparisons.
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Supplemental Experimental Procedures

Study Population
The following were the inclusion criteria: healthy men between ages 18 and 65 years with BMI between 18 and 40 kg/m 2 . We focused our recruitment on younger, leaner men since they were more likely to have detectable cold-stimulated BAT. Volunteers could not have participated in a clinical trial and received either an investigational or a marketed drug, or donated blood, within two months prior to the start of the study. The exclusion criteria were the following: women; history of any local or systemic infectious disease with fever or requiring antibiotic within four weeks of drug administration; a QTc interval above normal or the current use of any concomitant QT-prolonging drug; a clinically-significant abnormal ECG; a laboratory test result that is outside more than 1.5-fold outside the normal range and/or was judged to be clinically significant; current addiction to alcohol or substances of abuse; mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation; the use of a course of systemic corticosteroids or other medication known to cause insulin resistance in previous six weeks; the use of any medication known to be a CYP2D6 substrate; a diagnosis of bladder outlet obstruction or the use of antimuscarinic medications for the treatment of overactive bladder; and the use of beta adrenergic receptor blockers or calcium channel blockers. Since BAT activity is affected by the sympathetic nervous system and may be modulated by thyroid function, the following conditions were contraindicated: subjects with hyperthyroidism or hypothyroidism, hypertension (even if controlled with medications), heart disease (including CAD and CHF), cardiac arrhythmias, diabetes, unstable vasomotor system, or those taking monoamine oxidase inhibitors. Because the goal was to study adult human brown adipose tissue, children were not eligible to participate. Special classes of subjects, such as prisoners, institutionalized individuals, or others who may be considered vulnerable populations were also not involved in this study.
Of note, one subject withdrew from the study several weeks after the efficacy of mild cold exposure and mirabegron were evaluated and did not receive placebo.
Clinical Measurements
We measured blood pressure and heart rate using a SureSigns VS3 vital signs monitor (Philips Healthcare). We assessed calculated metabolic rate (RMR) using a Sensormedics Laboratories); for the four subjects whose concentrations were below the assay detection limit, we imputed the half-minimum value. Serum non-esterified fatty acids (NEFA), lactic acid, free T4, total T3, and glucagon were measured using standard procedures at the Laboratory Corporation of American (Burlington, NC). Serum β-hydroxybutyrate was measured using the LiquiColor kit (Stanbio Laboratories) by the JDC Specialized Assay Core.
Study Day and Imaging Protocol
We asked subjects to continue their standard weight-maintenance diets over the course of their participation and to refrain from caffeine and alcohol intake for 48 hours prior to each study day. The evening before a study day, subjects were admitted to the BIDMC clinical research center (CRC) and began fasting from 12 am onward. Room temperature was maintained above 23 °C. Upon waking the next morning, subjects donned a standard hospital scrub suit. We recorded vital signs every 15 minutes until the end of the study day. RMR was measured 30 minutes after the subjects awoke, and depending on the study day, we gave one of two stimuli: (Malik et al., 2012) .
We then measured RMR a second time. For each subject, we compared the average systolic blood pressure (BP), diastolic BP, and heart rate (HR) over two time intervals: during the hour prior to intervention (3 measures) and then for placebo and mirabegron, from 210 to 250 minutes afterward (3 measures), which represented the time of predicted peak activity of mirabegron (Malik et al., 2012) . Of note, for cold exposure, the second time interval was from 60 to 90 minutes (3 measures) after the initiation of cooling, which corresponds to the period when the radiotracer was distributing through the body (Cypess et al., 2012) .
Sixty minutes after . Although a ratio of two activities, the denominators are different, so the SUV therefore has the units of "SUV*g/mL":
[SUV *(mCi/mL)/(mCi/g)  SUV*g/mL]. BAT activity in each pixel was defined as the product of the volume of BAT in mL and its mean SUV (mL*SUVmean*g/mL).
We calculated a subject's total detectable BAT metabolic activity by taking the sum of the measured BAT activity in the principal cervical, supraclavicular, and anterior thoracic adipose tissue depots from vertebral level C3 to T7 as well as the BAT in the paraspinal, periaortic, perihepatic, perirenal and perisplenic fat depots. We calculated the change in drug-and coldinduced BAT activity by taking the difference between the activities measured during the placebo-and drug-dosing or cold-exposure days. Maximal glucose uptake (SUVmax) in the myocardium, subcutaneous abdominal WAT, erector spinae skeletal muscle, and liver were quantified as described (Cypess et al., 2012) . In brief, we identified the SUVmax measured in regions of interest in six consecutive axial slices in the left ventricle, white adipose tissue of the subcutaneous lumbar region, erector spinae skeletal muscle, and right lobe of the liver.
LC-MS/MS Analyses of Mirabegron
Detection and 
Sample Size Calculation and Statistical Analysis
In our prior studies of cold-exposed men, log 10 BAT activity following cold exposure was normally distributed with a mean of 1.47 and standard deviation of 0.72. By studying ten subjects, we estimated to have 80% power (α=0.05) to detect a difference in the mean response of matched pairs to mirabegron vs. placebo equal to -.716 or +.716, which corresponded to 50% in the log scale and 20% in the natural scale of the efficacy of cold activation. In our previous studies, the rate of detection of cold-activated BAT was 66%, so we estimated that studying fifteen subjects with cold exposure would yield at least ten subjects with detectable BAT activity who could proceed to evaluation of placebo and 200 mg mirabegron. Of note, the difference between placebo and drug-induced log 10 BAT activity, the endpoint used in the power calculation, had a p < 0.001 when using Student's t-test. The difference in the non-transformed BAT activity had a p = 0.001 when using Wilcoxon sign-ranks test.
